LITTLE ROCK, AR - The Winthrop P. Rockefeller Cancer Institute is recruiting people with skin cancer for the next phase of study on the safety and effectiveness of a treatment for advanced melanoma.
Specialists are studying whether people with the disease will respond favorably to Allovectin-7(R) in comparison with those treated with standard chemotherapy, the institute said in a news release Wednesday. About 375 patients will be enrolled.
Participants must be at least 18 and have recurrent metastatic melanoma with at least one tumor large enough to inject, about the size of a pea. Those who have received chemotherapy previously for melanoma cannot participate.